Exhibit 10.15

SECTION B—SUPPLIES OR SERVICES AND PRICES/COSTS

B.1. BRIEF DESCRIPTION OF SUPPLIES OR SERVICES

This project from the Department of Health and Human Services (HHS) through the Office of Public Health Emergency Medical Countermeasures (OPHEMC) within the Office of Public Health Emergency Preparedness (OPHEP) provides incremental multi-year funding for cost-reimbursable contracts for the development of antigen sparing approaches and products used as or with pandemic influenza vaccines leading towards U.S.-licensure from U.S.-based manufacturing sites for products not readily available at the onset of an influenza pandemic. The approach may include adjuvants, other biologicals, or medical delivery devices that when used with pre-pandemic and pandemic influenza vaccines afford enhanced immunogenicity (fewer immunizations) and/or an antigen sparing effects (less antigen utilization). The objective of this project is to stretch the domestic influenza vaccine supply in the event of an influenza pandemic.

B.2. HHSAR 352.232-74 Estimated Cost and Fixed Fee — Incrementally Funded Contract (Apr 1984)

(a) It is estimated that the total cost to the Government for full performance of this contract will be $128,511,517, of which the sum of $[***] represents the estimated reimbursable costs and $[***] represents the fixed-fee.

(b) Total funds currently available for payment and allotted to this contract are $14,454,917, of which $[***] represents the estimated reimbursable costs and $[***] represents the fixed-fee. For further provisions on funding, see the Limitation of Funds clause.

(c) It is estimated that the amount currently allotted will cover performance through March 31, 2008.

(d) The Contracting Officer may allot additional funds to the contract without the concurrence of the Contractor

B3. Cancellation Ceiling

(a) This clause does not apply when the contract is fully funded.

(b) The total funding in B.2 (c) includes an amount that covers the cancellation charge described in FAR 52.217-2, Cancellation Under Multi-year Contracts. The cancellation charge shall not exceed 100% of total funding under B.2 (b) above (insert dollar amount or express as a percentage of total funding under B.2 (b).

B.4. CONTRACT LINE ITEM NUMBERS (CLINS)

ITEM		SUPPLIES / SERVICES		QTY/UNIT		EST. COST		FIXED FEE		TOTAL EST. CPFF
0001		Product Development Plan (milestone 1)		1 Job		$[***]		$[***]		$[***]
0002		Non-Clinical Development, Clinical Development, and Regulatory Licensure Plans (milestone 2)		1 Job		$[***]		$[***]		$[***]

Contract No. HHSO100200700031C		Page 2 of 29

ITEM		SUPPLIES / SERVICES		QTY/UNIT		EST. COST		FIXED FEE		TOTAL EST. CPFF
0001		Product Development Plan (milestone 1)		1 Job		$[***]		$[***]		$[***]
0002		Non-Clinical Development, Clinical Development, and Regulatory Licensure Plans (milestone 2)		1 Job		$[***]		$[***]		$[***]
0003		Production Plan (milestone 3)		1 Job		$[***]		$[***]		$[***]
0004		Contractor Defined Milestones (milestone 4); See milestone 4 of the Statement of Work for key elements		1 Job		$[***]		$[***]		$[***]
0005		Technical Progress Reports and Executive Summary		12 reports per year		$[***]		$[***]		$[***]
0006		Final Report		1 report		$[***]		$[***]		$[***]

Contract No. HHSO100200700031C		Page 3 of 29

SECTION C — DESCRIPTION/SPECIFICATIONS

C.1. BACKGROUND/STATEMENT OF WORK

Purpose

     The purpose of this contract is to support advanced stage development of enhanced immunity and/or antigen-sparing strategies for pandemic influenza vaccination leading toward submission of a U.S. licensure application and development of required industrial capacity to support implementation of the antigen sparing strategy with pandemic influenza vaccine at full production capacity at or before the onset of a pandemic. Incremental multi-year funding for this cost-reimbursement contract is provided to your organization to support this effort. Ultimately, these antigen-sparing influenza vaccines or products shall be produced at one or more Food and Drug Administration (FDA)-licensed manufacturing facilities and shall provide sufficient surge capacity to contribute substantially to U.S. and ideally global vaccine needs during an influenza pandemic.

Objectives

Using intellectual property to which the company has unencumbered and documented access and documents “freedom to operate,” the contractor shall accomplish the following objectives associated with advanced development of a pandemic influenza vaccine antigen-sparing technology:

a) Conduct preclinical and clinical testing to assess the safety, immunogenicity and efficacy, as required by the FDA of the antigen-sparing strategy, and to define the type and magnitude of the antigen sparing effect for monovalent influenza vaccine against novel influenza strains (i.e., H5N1 or other subtypes not currently circulating among people) that are considered to have pandemic potential. Monovalent vaccines against novel influenza strains may be manufactured by the Contractor or subcontractor at a facility in compliance with current Good Manufacturing Practices (cGMP) guidelines and current World Health Organization (WHO) biosafety guidelines for pandemic influenza vaccine manufacturing. (2005).

b) Develop a preclinical and clinical manufacturing and testing plan with the supportive regulatory development plan that will lead to submission of a licensure application. The contractor should seek guidance from the FDA on the clinical development plan for their antigen-sparing products and should indicate where necessary that the clinical development plan reflects FDA’s guidance.

c) Develop a plan to manufacture the antigen-sparing pandemic influenza vaccine or products in a licensed facility based in the U.S. or, for a product with long-term stability that is suitable for stockpiling at an FDA-licensed facility in the U.S. or at a foreign site with a capacity to support rapid stockpile purchases commensurate with U.S. pandemic influenza vaccine needs.

Activities that may be supported by this contract shall include product toxicology studies in animals, clinical lot manufacturing including consistency lots for usage as or with pandemic influenza vaccines, clinical evaluation studies of the antigen-sparing strategy for safety and immunogenicity, process and manufacturing scale up development, product lot release assay development and process validation; product-dedicated manufacturing equipment; facility concept design and facility validation. USG support shall not be provided for building a manufacturing facility or purchasing an existing facility.

Additional information

This advanced development contract is milestone-driven and funding is expected to occur in phases. Periodic assessments of progress will be conducted by DHHS. Continuation of effort on initial and subsequent milestones and associated funding will be based on contractor performance, timeliness and quality of deliverables, availability of other antigen sparing strategies and products deemed more advantageous to the USG, and consultations between the contractor, DHHS, and interagency

Contract No. HHSO100200700031C		Page 4 of 29

working group members. This paragraph does not limit the Government’s rights under contract clauses that include, but are not limited to, FAR 52.217-2, Cancellation Under Multi-year contracts, and 52.249-6, Termination (Cost-Reimbursement).

Statement of Work

     Independently and not as an agent of the government, the contractor shall furnish all the necessary services, qualified personnel, materials, equipment, and facilities not otherwise provided by the government as needed to perform the work described below.

     The contract will include a Contractor Work Plan (CWP) that describes the activities to be performed and a single Gantt chart to include all activities described in the CWP with a time-phased and task-linked budget. The level of detail contained in the CWP and the corresponding Gantt chart will be sufficient to facilitate management and execution of the contract.

Milestones

I.

Milestone 1: Within three (3) months of contract award, the Contractor shall provide to the HHS for review and acceptance a milestone-driven Product Development Plan for development of antigen sparing pandemic influenza vaccine or related products. This plan shall include: a) pre-clinical studies, as needed, to support clinical testing; b) process development and scale up manufacturing of monovalent pandemic influenza vaccine product or use with this vaccine to novel influenza viruses; c) clinical and consistency lot manufacturing for FDA product licensure, d) general clinical development plan including development and validation of clinical sample assays (see Milestone 2); e) product lot release assay development and validation, and f) regulatory master plan for product licensure (see Milestone 2). Pandemic monovalent influenza vaccine used in these studies may be produced by the Contractor or a corporate partner.

II.

Milestone 2: Within six (6) months of contract award, the Contractor shall submit to HHS for review and acceptance complete milestone-driven Non-Clinical Development, Clinical Development, and Regulatory Licensure Plans to initiate vaccine and/or device development, pre-clinical studies, or clinical studies, as appropriate based on the current stage of development and as outlined in the development, testing, and manufacturing plan.

	A.		A pre-clinical testing plan that is integrated with the clinical testing and manufacturing plans using the most current and available information including consultation with Center for Biologics Evaluation and Research (CBER) at FDA.
	B.		A clinical testing plan that is integrated with the pre-clinical testing and manufacturing plans using the most current and available information including consultation with FDA CBER. Clinical trials performed as a result of this contract shall include any of Phase I, Phase 2, and Phase 3 trials, as needed to achieve U.S. licensure. Trials should include children, adults, and the elderly, as needed, to support licensure for both low and high-risk populations. Given the duration, cost, and importance of clinical trials, the schedule for each clinical trial should clearly indicate key outcomes, populations, study sites and collaborators, analytic strategy, sample size, timelines, and other key components. Studies should be done using monovalent influenza vaccine to a novel influenza strain with and without the product providing enhanced immunity and/or antigen-sparing effect.
	C.		A regulatory plan that is integrated with all products and clinical testing and manufacturing activities using the most current and available information including consultation with FDA CBER.

III.

Milestone 3: Within twelve (12) months of contract award, the Contractor shall provide the USG

Contract No. HHSO100200700031C		Page 5 of 29

with one or more of the following, as appropriate for the antigen sparing product(s) being developed:

	A.		A Production Plan to produce at least 150 million doses of the monovalent antigen sparing pandemic influenza vaccine within a 6 month period.
	B.		If the antigen sparing strategy relies on a non-vaccine product that is not suitable for long term stockpiling, the Contractor must provide a Production Plan to produce at least 150 million units within 6 months or requiring no more than 1-month lead time before the first units are produced of the product at a licensed or licensable U.S.-based facility.
	C.		If the antigen sparing strategy uses a delivery device that is suitable for long term stockpiling, the Contractor must provide a Production Plan to produce and make available to the U.S. Government first within a 6 month manufacturing period at a U.S.-licensed facility and at reasonable cost, a quantity commensurate with delivery of at least 150 million vaccine doses.
	D.		A Production Plan shall contain the concept architectural and mechanical engineering descriptions, drawings of functional areas, and flow diagrams of personnel, product, raw materials, and waste for the manufacturing facilities and ancillary product testing laboratories. Major product related equipment should be indicated in the description and drawings that would permit vaccine or product production for pandemic purposes as levels and timeframes indicated above.

The manufacturing facility and production processes shall be maintained in compliance with current Good Manufacturing Practices (cGMP) for all manufacturing operations and current Good Laboratory Practices (cGLP) for testing laboratories, as applicable. Ability to meet standards for Biosafety Level (BSL) 2 + and 3 as described in WHO biosafety guidelines for pandemic influenza vaccine manufacturing may be necessary, if the Contractor will be handling and testing highly pathogenic avian influenza viruses or derivatives to generate pandemic influenza vaccines.

IV.

Milestone 4: Contactor defined milestones. The Contractor shall provide a work breakdown structure including comprehensive and integrated timelines (Gantt chart) and major milestones to complete the remaining the scope of work as relevant given the stage of vaccine and/or device development and evaluation toward product licensure. The Contractor shall propose milestones at which time data will be presented summarizing results of prior activities and new plans and protocols that will be submitted for review and approval in order to guide all subsequent activities. Potential milestones may include FDA acceptance of an IND application, production of an investigational lot of vaccine and/or delivery system, validation of facilities, systems, and equipment, validation of QC lot release product methods, validation of manufacturing processes, stability study programs, consistency lot manufacturing, completion of a clinical trial and progress to a new phase of vaccine evaluation, submission of a licensure application, an option for additional clinical studies of pandemic vaccines etc.

[END OF STATEMENT OF WORK]

Meetings and conferences:

The Contractor shall participate in regular meetings to coordinate and oversee the contract effort as directed by the Project Officer. Such meetings may include, but are not limited to, meetings of all Contractors and subcontractors to discuss clinical manufacturing progress, product development, product assay development, scale up manufacturing development, clinical sample assays development, preclinical/clinical study designs and regulatory issues,; meetings with individual contractors and other HHS officials to

Contract No. HHSO100200700031C		Page 6 of 29

discuss the technical, regulatory, and ethical aspects of the program; and meetings with technical consultants to discuss technical data provided by the Contractor. Monthly teleconferences with the Contractor and subcontractors with HHS officials will be held at times and dates to be determined to review technical and product development progress.

Contract No. HHSO100200700031C		Page 7 of 29

C.2. REPORTING REQUIREMENTS

In addition to those reports required by other terms of this contract, the Contractor(s) shall submit to the Contracting Officer and the Project Officer technical progress reports covering the work accomplished during each reporting period on a periodical basis as set forth below and as may be otherwise established by the Project Officer as circumstances require. These reports are subject to the technical inspection and requests for clarification by the Project Officer. These reports shall be brief and factual and prepared in accordance with the following format:

I.

Technical Progress Reports: On the fifteenth of each month for the previous calendar month or within fifteen days past the achievement of prescribed project milestones, the Contractor shall submit to the Project Officer and the Contracting Officer. The frequency of Technical Progress Reporting will be determined by the Contracting Officer and Project Officer after contract award. The format and type of Technical Progress Report and Executive Summary will be provided by the Project Officer. Technical Progress Reports will include project timelines and milestones and summaries of product manufacturing, testing, and clinical evaluation. A Technical Progress Report will not be required for the period when the Final Report is due. The Contractor shall submit one copy of the Technical Progress Report electronically via e-mail. Any attachments to the e-mail report shall be submitted in Microsoft Word or Word Perfect, Microsoft Excel, Microsoft Project Manger, and/or Adobe Acrobat PDF files. Such reports shall include the following specific information:

	A.		Title page containing Technical Progress Report, the contract number and title, the period of performance or milestone being reported, the contractor’s name, address, and other contact information, the author(s), and the date of submission;
	B.		Introduction/Background — An introduction covering the purpose and scope of the contract effort;
	C.		Progress — The report shall detail, document, and summarize the results of work performed, test results, and milestones achieved during the period covered. Also to be included is a summary of work planned for the next reporting period;
	D.		Issues — Issues resolved, new issues, and outstanding issues are enumerated with options and recommendations for resolution. An explanation of any difference between planned progress and actual progress, why the differences have occurred, and, if project activity is delinquent, then what corrective steps are planned. Revised timelines are provided.
	E.		Invoices — Summary of any invoices submitted during the reporting period.
	F.		Action Items — Summary table of activities or tasks to be accomplished by a certain date and by whom.
	G.		Distribution List — A list of persons receiving the Technical Progress report
	H.		Attachments — Results on the project are provided as attachments

II.

The Executive Summary, which shall accompany each Technical Progress Report, will be formatted in Microsoft Power Point presentations and include the following:

	A.		Title page containing Executive Title, the contract number and title, the period of performance or milestone being reported, the contractor’s name and the date of submission;
	B.		Project Progress presented as milestone events, test results, tasks, and other activities achieved during the reporting period as talking point bullets;
	C.		Project Issues presented headings and each item as a talking point bullet.

III.

Final Reports — By the expiration date of the contract, the Contractor shall submit a comprehensive Final Report that shall detail, document, and summarize the results of the entire contract work. The report shall explain comprehensively the results achieved. A draft Final Report will be submitted to the Project Officer for review and revision, then the original, four copies, and an electronic file containing the Final Report with revisions shall be submitted to the Project Officer for distribution to the Contracting Officer and the Program.

Contract No. HHSO100200700031C		Page 8 of 29

SECTION D—PACKAGING, MARKING AND SHIPPING

D.1. SHIPPING

I. Method of Delivery

Unless otherwise specified by the Contracting Officer or the Contracting Officer’s representative, delivery of items, to be furnished to the government under this contract (including invoices), shall be made by first class mail.

II. Addressees — For all contract deliverables.

Project Officer		Contracting Officer
HHS/OPHEP/OPHEMC		HHS/OPHEP/OPHEMC
300 Independence Avenue SW		300 Independence Avenue SW
Room G640		Room G640
Washington, D.C. 20201		Washington, D.C. 20201

Contract No. HHSO100200700031C		Page 9 of 29

SECTION E—INSPECTION AND ACCEPTANCE

The Contracting Officer or the duly authorized representative will inspect and accept materials and services to be delivered under the contract. Contractor inspector is hereby noted, as the Project Officer and place of inspection will be the contractor’s facilities. In addition, the following clause is incorporated by reference:

FAR Clause No.52.246-9, INSPECTION OF RESEARCH AND DEVELOPMENT (SHORT FORM) (APR 1984)

Contract No. HHSO100200700031C		Page 10 of 29

SECTION F—DELIVERIES OR PERFORMANCE

F.1. PERIOD OF PERFORMANCE

The period of performance of this contract is from the date of contract award to 60 months after contract award.

Delivery will be required F.O.B. Destination as set forth in FAR 52.247-35, F.O.B. DESTINATION, WITHIN CONSIGNEE’S PREMISES (APR 1984).

F.2. Technical Report Requirements

Item		Deliverable		Quantity		Due Date
1.		Technical Progress Report		Original — C.O. 2 Copies — P.O. 1 Electronic Copy — P.O.		1st Report due on/before February 15, 2007; thereafter, due on/before the 15th of the month or milestone following each reporting period. Not due when Final is due.
2.		Executive Summary		Original — C.O. 2 Copies — P.O. 1 Electronic Copy — P.O.		1st Report due on/before February 15, 2007; thereafter, due on/before the 15th of the month following each anniversary date of the contract. Not due when Final is due.
3.		Final Report		Original — C.O. 2 Copies — P.O. 1 Electronic Copy — P.O.		Due on/before the completion date of the contract.

F.3. Contract Deliverables

Milestones		Deliverable		Quantity		Due Date
1.		Product Development Plan (milestone 1)		Original — C.O. 2 Copies — P.O. 1 Electronic Copy — P.O.		Three (3) months after contract award.
2.		Non-Clinical Development, Clinical Development, and Regulatory Licensure Plans (milestone 2)		Original — C.O. 2 Copies — P.O. 1 Electronic Copy — P.O.		Within Six (6) months after contract award.
3.		Production Plan (milestone 3)		Original — C.O. 2 Copies — P.O. 1 Electronic Copy — P.O.		Within Twelve (12) months after contract award.
4.		Contractor Defined Milestones (milestone 4)		Original — C.O. 2 Copies — P.O. 1 Electronic Copy — P.O.		Performance of Contractor defined Milestones within 60 months after contract award.

Contract No. HHSO100200700031C		Page 11 of 29

F.4. STOP WORK ORDER

The following clause is incorporated by reference:

FAR CLAUSE 52.242-15, STOP WORK ORDER (AUG 1989) with ALTERNATE I (APR 1984)

Contract No. HHSO100200700031C		Page 12 of 29

SECTION G.—CONTRACT ADMINISTRATION DATA

G.1. CONTRACTING OFFICER

1) The Contracting Officer is the only individual who can legally commit the Government to the expenditure of public funds. No person other than the Contracting Officer can make any changes to the terms, conditions, general provisions or other stipulations of this contract.

2) The Contracting Officer is the only person with authority to act as agent of the Government under this contract. Only the Contracting Officer has authority to: (1) direct or negotiate any changes in the statement of work; (2) modify or extend the period of performance; (3) change the delivery schedule; (4) authorize reimbursement to the Contractor any costs incurred during the performance of this contract; or (5) otherwise change any terms and conditions of this contract.

3) No information, other than that which may be contained in an authorized modification to this contract, duly issued by the Contracting Officer, which may be received from any person employed by the United States Government, or otherwise, shall be considered grounds for deviation from any stipulation of this contract.

G.2. PROJECT OFFICER

The Government’s Project Officer(s) will be identified by modification upon contract execution.

The Project Officer is responsible for: (1) monitoring the Contractor’s technical progress, including the surveillance and assessment of performance and recommending to the Contracting Officer changes in requirements; (2) interpreting the statement of work and any other technical performance requirements; (3) performing technical evaluation as required; (4) performing technical inspections and acceptances required by this contract; and (5) assisting in the resolution of technical problems encountered during performance.

G.3. KEY PERSONNEL

Pursuant to HHSAR Clause 352.270-5, Key Personnel, incorporated in Section I of this contract, the following individuals are considered to be essential to the work being performed hereunder:

Name		Title
Gregory M. Glenn, M.D		Principal Investigator
Denise G. Courbron, MS, PMP		Project Manager
Larry R. Ellingsworth, Ph.D		Vice President, Research
Diane Epperson, Ph.D		Manager, Preclinical Immunology
Sarah Alcott Frech, D.V.M.., M.P.H		Vice President, Clinical Development
Mervyn L. Hamer		Vice President, Operations
Kimber L. Poffenberger, Ph.D.		Vice President, Regulatory Affairs
Robert Seid, Ph.D.		Vice President, Formulation
Jeffrey L. Wells		Director, Quality Systems

Contract No. HHSO100200700031C		Page 13 of 29

Prior to diverting any of the specified individuals to other programs, the Contractor shall notify the Contracting Officer reasonably in advance and shall submit justification (including proposed substitutions) in sufficient detail to permit evaluation of the impact on the program. No diversion shall be made by the Contractor without the written consent of the Contracting Officer; provided, that the Contracting Officer may ratify in writing such diversion and such ratification shall constitute the consent of the Contracting Officer. The contract may be modified from time to time during the course of the contract to either add or delete personnel, as appropriate.

G. 4. INVOICE SUBMISSION

Invoices will be submitted monthly in accordance with “Invoice/Financing Request Instructions” attached to this contract.

G. 5. CONTRACT FINANCIAL REPORT

Financial reports will be submitted to the address specified in Block 7 of face page of the contract. Normally, reports are due quarterly. Examples of the cost elements to be reported include the following:

Expenditure Category

1.

Direct Labor

	a.		Principal Investigator
	b.		Co-Principal Investigator

	2.		Personnel — Other
	3.		Fringe Benefits
	4.		Materials/Supplies
	5.		Travel
	6.		Consultant Costs
	7.		Subcontract Costs
	8.		Other Direct Costs
	9.		Clinical Trials Costs
	10.		Indirect Cost
	11.		Fee
	12.		Total Cost

G. 6. INDIRECT COST RATES

Profit making organizations will negotiate provisional and/or final indirect cost rates with their cognizant Government Audit Agency.

G. 7. POST AWARD EVALUATION OF PAST PERFORMANCE

Interim and final evaluations of contractor performance shall be conducted on this contract in accordance with FAR 42.15. The final performance evaluation shall be completed at the time of completion of work. Interim and final evaluations will be submitted to the Contractor as soon as practicable. The Contractor will be permitted thirty days to review the document and to submit additional information or a rebutting statement.

G.8. GOVERNMENT PROPERTY

a.

In addition to the requirements of the clause, GOVERNMENT PROPERTY, incorporated in SECTION I of this contract, the Contractor shall comply with the provisions of HHS Publication, “Contractor’s Guide for Control of Government Property,” which is incorporated into this contract

Contract No. HHSO100200700031C		Page 14 of 29

by reference. This document can be accessed at: http://www.knownet.hhs.gov/log/AgencyPolicy/HHSLogPolicy/contractorsguide.htm. Among other issues, this publication provides a summary of the Contractor’s responsibilities regarding purchasing authorizations and inventory and reporting requirements under the contract. A copy of this publication is available upon request to the Contracts Property Administrator.

b.

Notwithstanding the provisions outlined in the HHS Publication, “Contractor’s Guide for Control of Government Property,” which is incorporated in this contract in paragraph a. above, the contractor shall use the form entitled, “Report of Government Owned, Contractor Held Property” for performing annual inventories required under this contract. This form is included as an attachment in SECTION J of this contract.

Contract No. HHSO100200700031C		Page 15 of 29

SECTION H—SPECIAL CONTRACT REQUIREMENTS

H. 1. HUMAN SUBJECTS

Research involving human subjects shall not be conducted under this contract until the protocol developed in Milestone 2 has been approved by DHHS, written notice of such approval has been provided by the Contracting Officer, and the Contractor has provided to the Contracting Officer a properly completed Optional Form 310 certifying Internal Review Board (IRB) review and approval of the protocol. The human subject certification can be met by submission of the Contractor’s self designated form, provided that it contains the information required by the Optional Form 310.

H. 2. HUMAN MATERIALS

It is understood that the acquisition and supply of all human specimen material (including fetal material) used under this contract will be obtained by the Contractor in full compliance with applicable State and Local laws and the provisions of the Uniform Anatomical Gift Act in the United States and that no undue inducements, monetary or otherwise, will be offered to any person to influence their donation of human material.

H. 3. ANIMAL WELFARE ASSURANCE

The Contractor shall obtain, prior to the start of any work under this contract, an approved Animal Welfare Assurance from the Office of Protection from Research Risks (OPRR), Office of the Director, NIH, as required by Section I-43-30 of the Public Health Service Policy on Humane Care and Use of Laboratory Animals. The Contractor shall maintain such assurance for the duration of this contract, and any subcontractors performing work under this contract involving the use of animals shall also obtain and maintain an approved Animal Welfare Assurance.

H. 4. CONFIDENTIALITY OF INFORMATION

The following information is covered by HHSAR 352.224-70, confidentiality of Information (APR 1984):

                         Data obtained from human subjects

H. 5. REVIEW AND APPROVAL

The Contractor shall not release any reports, manuscripts, press releases, or abstracts about the work being performed under this contract without written approval in advance from the Government.

H. 6. IDENTIFICATION AND DISPOSITION OF DATA

The Contractor will be required to provide certain data generated under this contract to the Department of Health and Human Services (DHHS). DHHS reserves the right to review any other data determined by DHHS to be relevant to this contract. The contractor shall keep copies of all data required by the Food and Drug Administration (FDA) relevant to this contract for the time specified by the FDA.

H. 7. EPA ENERGY STAR REQUIREMENTS

In compliance with Executive Order 12845 (requiring Agencies to purchase energy efficient computer equipment) all microcomputers, including personal computers, monitors, and printers that are purchased using Government funds in performance of a contract shall be equipped with or meet the energy efficient low-power standby feature as defined by the EPA Energy Star program unless the equipment always meets

Contract No. HHSO100200700031C		Page 16 of 29

EPA Energy Star efficiency levels. The microcomputer, as configured with all components, must be Energy Star compliant.

This low-power feature must already be activated when the computer equipment is delivered to the agency and be of equivalent functionality of similar power managed models. If the equipment will be used on a local area network, the vendor must provide equipment that is fully compatible with the network environment. In addition, the equipment will run commercial off-the-shelf software both before and after recovery from its energy conservation mode.

H.8. REPORTING MATTERS INVOLVING FRAUD, WASTE AND ABUSE

Anyone who becomes aware of the existence or apparent existence of fraud, waste and abuse in DHHS funded programs is encouraged to report such matters to the HHS Inspector General’s Office in writing or on the Inspector General’s Hotline. The toll-free number is 1-800-HHS-TIPS (1-800-447-8477). All telephone calls will be handled confidentially. The e-mail address is Htips@os.dhhs.gov.

Office of Inspector General
Department of Health and Human Services
TIPS HOTLINE
P.O. Box 23489
Washington, DC 20026

H.9. ACKNOWLEDGMENT OF FEDERAL FUNDING

A.

Section 507 of P.L. 104-208 mandates that contractors funded with Federal dollars, in whole or in part, acknowledge Federal funding when issuing statements, press releases, requests for proposals, bid solicitations and other documents. Contractors are required to state (1) the percentage and dollar amounts of the total program or project costs financed with Federal money, and (2) the percentage and dollar amount of the total costs financed by nongovernmental sources.

This requirement is in addition to the continuing requirement to provide an acknowledgment of support and disclaimer on any publication reporting the results of a contract funded activity.

B.

Publication and Publicity

The Contractor shall acknowledge the support of the Department of Health and Human Service, Office of Public Health Emergency Preparedness, Office of Research and Development Coordination whenever publicizing the work under this contract in any media by including an acknowledgment substantially as follows:

“This project has been funded in whole or in part with Federal funds from the Office of Public Health Emergency Preparedness, Office of Public Health Emergency Medical Countermeasures, under Contract No. HHSO100200700031C.

H.10. NEEDLE EXCHANGE

Pursuant to Section 505 of Public Law 105-78, contract funds shall not be used to carry out any program of distributing sterile needles or syringes for the hypodermic injection of any illegal drug. Section 505, however, is subject to the condition stated in Section 506. Specifically, Section 506 states that after March 31, 1998, a program for exchanging needles and syringes for used hypodermic needles and syringes may be carried out in a community if: (1) the Secretary of Health and Human Services determines that exchange projects are effective in preventing the spread of HIV and do not encourage the use of illegal drugs; and (2)

Contract No. HHSO100200700031C		Page 17 of 29

the project is operated in accordance with criteria established by the Secretary for preventing the spread of HIV and for ensuring that the project does not encourage the use of illegal drugs.

H.11 PRESS RELEASES

Pursuant to Section 508 of Public Law 105-78, the contractor shall clearly state, when issuing statements, press releases, requests for proposals, bid solicitations and other documents describing projects or programs funded in whole or in part with Federal money that: (1) the percentage of the total costs of the program or project which will be financed with Federal money; (2) the dollar amount of Federal funds for the project or program; and (3) the percentage and dollar amount of the total costs of the project or program that will be financed by nongovernmental sources.

H.12. PROHIBITION ON CONTRACTOR INVOLVEMENT WITH TERRORIST ACTIVITIES

The Contractor acknowledges that U.S. Executive Orders and Laws, including but not limited to Executive Order 13224 and Public Law 107-56, prohibit transactions with, and the provisions of resources and support to, individuals and organizations associated with terrorism. It is the legal responsibility of the contractor to ensure compliance with these Executive Orders and Laws. This clause must be included in all subcontracts issued under this contract.

H.13. MANUFACTURING STANDARDS

The Current Good Manufacturing Practice Regulations (cGMP) (21 CFR Parts 210-211) will be the standard to be applied for manufacturing, processing and packing of this therapeutic product.

If at any time during the life of the contract, the Contractor fails to comply with cGMP in the manufacturing, processing and packaging of this therapeutic product and such failure results in a material adverse effect on the safety, purity or potency of this therapeutic product (a material failure) as identified by CBER and CDER, the Contractor shall have thirty (30) calendar days from the time such material failure is identified to cure such material failure. If the Contractor fails to take such an action within the thirty (30) calendar day period, then the contract may be terminated.

The USG reserves the right to inspect the contractor’s facilities for cGMP compliance. HHS will audit manufacturing, testing and other relevant sites. Focus areas will include manufacturing, quality systems and regulatory affairs relative to the contract milestone activities within six (6) months of contract award. Any deficiencies observed in the audit will require remediation. Within three (3) months, a time-plan for remediation must be in place and remediation shall be complete within 12 months of award.

Contract No. HHSO100200700031C		Page 18 of 29

H.14. ANTI-LOBBYING PROVISIONS

The contractor is hereby notified of the restrictions on the use of Department of Health and Human Service’s funding for lobbying of Federal, State and Local legislative bodies.

Section 1352 of Title 10, United States Code (Public Law 101-121, effective 12/23/89), among other things, prohibits a recipient (and their subcontractors) of a Federal contract, grant, loan, or cooperative agreement from using appropriated funds (other than profits from a federal contract) to pay any person for influencing or attempting to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with any of the following covered Federal actions; the awarding of any Federal contract; the making of any Federal grant; the making of any Federal loan; the entering into of any cooperative agreement; or the modification of any Federal contract, grant, loan, or cooperative agreement. For additional information of prohibitions against lobbying activities see FAR Subpart 3.8 and FAR Clause 52.203-12.

In addition, the current Department of Health and Human Services Appropriations Act provides that no part of any appropriation contained in this Act shall be used, other than for normal and recognized executive-legislative relationships, for publicity or propaganda purposes, for the preparation, distribution, or use of any kit, pamphlet, booklet, publication, radio, television, or video presentation designed to support, or defeat legislation pending before the Congress, or any State or Local legislature except in presentation to the Congress, or any State or Local legislative body itself.

The current Department of Health and Human Services Appropriations Act also provides that no part of any appropriation contained in this Act shall be used to pay the salary or expenses of any contract or grant recipient, or agent acting for such recipient, related to any activity designed to influence legislation or appropriations pending before the Congress, or and State or Local legislature.

H.15. POSSESSION, USE AND TRANSFER OF SELECTED BIOLOGICAL AGENTS OR TOXINS

The contractor shall not conduct work involving select agents or toxins under this contract until it and any associated subcontractor(s) comply with the following:

For prime or subcontract awards to domestic institutions that possess, use, and/or transfer Select Agents under this contract, the institution must comply with the provisions of 42 CFR part 73, 7 CFR part 331, and/or 9 CFR part 121 (http://www.aphis.usda.gov/programs/ag_selectagent/FinalRule3-18-05.pdf), as required, before using DHHS funds for research involving Select Agents. No DHHS funds can be used for research involving Select Agents if the final registration certificate is denied.

For prime or subcontract awards to foreign institutions that possess, use, and/or transfer Select Agents under this contract, before using DHHS funds for any work directly involving the Select Agents, the foreign institution must provide information satisfactory to the DHHS that safety, security, and training standards equivalent to those described in 42 CFR part 73, 7 CFR part 331, and/or 9 CFR part 121 at:

are in place and will be administered on behalf of all Select Agent work sponsored by these funds. The process for making this determination includes inspection of the foreign laboratory facility by an HHS representative. During this inspection, the foreign institution must provide the following information: concise summaries of safety, security, and training plans; names of individuals at the foreign institution who will have access to the Select Agents and procedures for ensuring that only approved and appropriate individuals, in accordance with institution procedures, will have access to the Select Agents under the contract; and copies of or links to any applicable laws, regulations, policies, and procedures applicable to that institution for the safe and secure possession, use, and/or transfer of select agents. An DHHS-chaired committee of U.S. federal employees (including representatives of select DHHS grants/contracts and

Contract No. HHSO100200700031C		Page 19 of 29

scientific program management, CDC, Department of Justice and other federal intelligence agencies, and Department of State) will ultimately assess the results of the laboratory facility inspection, and the regulations, policies, and procedures of the foreign institution for equivalence to the U.S. requirements described in 42 CFR part 73, 7 CFR part 331, and/or 9 CFR part 121 (http://www.aphis.usda.gov/programs/ag_selectagent/FinalRule3-18-05.pdf). The committee will provide recommendations to the OPHEMC Director, DHHS. The Director (or designee) will make the approval decision and notify the Contracting Officer. The Contracting Officer will inform the prime contractor of the approval status of the foreign institution. No DHHS funds can be used for research involving Select Agents at a foreign institution until DHHS grants this approval.

Listings of HHS select agents and toxins, and overlap select agents or toxins as well as information about the registration process for domestic institutions, are available on the Select Agent Program Web site at http://www.cdc.gov/od/sap/ and http://www.cdc.gov/od/sap/docs/salist.pdf. Listings of USDA select agents and toxins as well as information about the registration process for domestic institutions are available on the APHIS/USDA website at:

http://www.aphis.usda.gov/programs/ag_selectagent/index.html; and
http://www.aphis.usda.gov/programs/ag_selectagent/ag_bioterr_forms.html.

For foreign institutions, see the NIAID Select Agent Award information:
http://www.niaid.nih.gov/ncn/clinical/default_biodefense.htm

Contract No. HHSO100200700031C		Page 20 of 29

PART II – CONTRACT CLAUSES

SECTION I — CONTRACT CLAUSES

ARTICLE I.1. GENERAL CLAUSES FOR A COST-REIMBURSEMENT RESEARCH AND DEVELOPMENT CONTRACT — FAR 52.252-2, CLAUSES INCORPORATED BY REFERENCE (FEBRUARY 1998)

This contract incorporates the following clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at this address: http://www.acquisition.gov/comp/far/index.html.

I.1. GENERAL CLAUSES

General Clauses for a Cost-Reimbursement Research and Development Contract

FAR		52.202-1		Jul 2004		Definitions
FAR		52.203-3		Apr 1984		Gratuities (Over $100,000)
FAR		52.203-5		Apr 1984		Covenant Against Contingent Fees (Over $100,000)
FAR		52.203-6		Sep 2006		Restrictions on Subcontractor Sales to the Government (Over $100,000)
FAR		52.203-7		Jul 1995		Anti-Kickback Procedures (Over $100,000)
FAR		52.203-8		Jan 1997		Cancellation, Rescission, and Recovery of Funds for Illegal or Improper Activity (Over $100,000)
FAR		52.203-10		Jan 1997		Price or Fee Adjustment for Illegal or Improper Activity (Over $100,000)
FAR		52.203-12		Sep 2003		Limitation on Payments to Influence Certain Federal Transactions (Over $100,000)
FAR		52.204-4		Aug 2000		Printed or Copied Double-Sided on Recycled Paper (Over $100,000)
FAR		52.204-7		Oct 2003		Central Contractor Registration
FAR		52.209-6		Sep 2006		Protecting the Government’s Interests When Subcontracting With Contractors Debarred, Suspended, or Proposed for Debarment (Over $25,000)
FAR		52.215-2		Jun 1999		Audit and Records — Negotiation (Over $100,000)
FAR		52.215-8		Oct 1997		Order of Precedence — Uniform Contract Format
FAR		52.215-10		Oct 1997		Price Reduction for Defective Cost or Pricing Data
FAR		52.215-12		Oct 1997		Subcontractor Cost or Pricing Data (Over $500,000)
FAR		52.215-14		Oct 1997		Integrity of Unit Prices (Over $100,000)

Contract No. HHSO100200700031C		Page 21 of 29

FAR		52.215-15		Oct 2004		Pension Adjustments and Asset Reversions
FAR		52.215-18		Jul 2005		Reversion or Adjustment of Plans for Post-Retirement Benefits (PRB) other than Pensions
FAR		52.215-19		Oct 1997		Notification of Ownership Changes
FAR		52.215-21		Oct 1997		Requirements for Cost or Pricing Data or Information Other Than Cost or Pricing Data – Modifications
FAR		52.216-7		Dec 2002		Allowable Cost and Payment
FAR		52.216-8		Mar 1997		Fixed Fee
FAR		52.217-2		Oct 1997		Cancellation Under Multi-Year Contracts
FAR		52.219-8		May 2004		Utilization of Small Business Concerns (Over $100,000)
FAR		52.219-9		Sep 2006		Small Business Subcontracting Plan (Over $500,000)
FAR		52.219-16		Jan 1999		Liquidated Damages — Subcontracting Plan (Over $500,000)
FAR		52.222-2		Jul 1990		Payment for Overtime Premium (Over $100,000) (Note: The dollar amount in paragraph (a) of this clause is $0 unless otherwise specified in the contract.)
FAR		52.222-3		Jun 2003		Convict Labor
FAR		52.222-21		Feb 1999		Prohibition of Segregated Facilities
FAR		52.222-26		Apr 2002		Equal Opportunity
FAR		52.222-35		Sep 2006		Equal Opportunity for Special Disabled Veterans, Veterans of the Vietnam Era, and Other Eligible Veterans
FAR		52.222-36		Jun 1998		Affirmative Action for Workers with Disabilities
FAR		52.222-37		Sep 2006		Employment Reports on Special Disabled Veterans, Veterans of the Vietnam Era, and Other Eligible Veterans
FAR		52.223-6		May 2001		Drug-Free Workplace
FAR		52.223-14		Aug 2003		Toxic Chemical Release Reporting (Over $100,000)
FAR		52.225-1		Jun 2003		Buy American Act – Supplies
FAR		52.225-13		Feb 2006		Restrictions on Certain Foreign Purchases
FAR		52.227-1		Jul 1995		Authorization and Consent, Alternate I (Apr 1984)
FAR		52.227-2		Aug 1996		Notice and Assistance Regarding Patent and Copyright Infringement (Over $100,000)
FAR		52.227-11		Jan 1997		Patent Rights — Retention by the Contractor (Short Form) (Note: In accordance with FAR 27.303(a)(2), paragraph (f) is modified to include the requirements in FAR 27.303(a)(2)(i) through (iv). The frequency of reporting in (i) is annual.

Contract No. HHSO100200700031C		Page 22 of 29

FAR		52.227-14		Jun 1987		Rights in Data – General
FAR		52.232-9		Apr 1984		Limitation on Withholding of Payments
FAR		52.232-17		Jun 1996		Interest (Over $100,000)
FAR		52.232-18		Apr1984		Availability of Funds
FAR		52.232-20		Apr 1984		Limitation of Cost (applies when contract is fully funded)
FAR		52.232-22		Apr 1984		Limitation of Funds (applies when contract is incrementally funded)
FAR		52.232-23		Jan 1986		Assignment of Claims
FAR		52.232-25		Oct 2003		Prompt Payment, Alternate I (Feb 2002)
FAR		52.232-33		Oct 2003		Payment by Electronic Funds Transfer—Central Contractor Registration
FAR		52.233-1		Jul 2002		Disputes
FAR		52.233-3		Aug 1996		Protest After Award, Alternate I (Jun 1985)
FAR		52.233-4		Oct 2004		Applicable Law for Breach of Contract Claim
FAR		52.242-1		Apr 1984		Notice of Intent to Disallow Costs
FAR		52.242-3		May 2001		Penalties for Unallowable Costs (Over $650,000)
FAR		52.242-4		Jan 1997		Certification of Final Indirect Costs
FAR		52.242-13		Jul 1995		Bankruptcy (Over $100,000)
FAR		52.243-2		Aug 1987		Changes — Cost Reimbursement, Alternate V (Apr 1984)
FAR		52.244-2		Aug 1998		Subcontracts, Alternate II (Aug 1998) *If written consent to subcontract is required, the identified subcontracts are listed in ARTICLE B, Advance Understandings.
FAR		52.244-5		Dec 1996		Competition in Subcontracting (Over $100,000)
FAR		52.244-6		Sep 2006		Subcontracts for Commercial Items
FAR		52.245-5		May 2004		Government Property (Cost-Reimbursement, Time and Material, or Labor-Hour Contract)
FAR		52.246-23		Feb 1997		Limitation of Liability (Over $100,000)
FAR		52.246-25		Feb 1997		Limitation of Liability — Services
FAR		52.249-6		May 2004		Termination (Cost-Reimbursement)
FAR		52.249-14		Apr 1984		Excusable Delays

Contract No. HHSO100200700031C		Page 23 of 29

FAR		52.253-1		Jan 1991		Computer Generated Forms
HHSAR		352.202-1		Jan 2001		Definitions — with Alternate paragraph (h) (Jan 2001)
HHSAR		352.216-72		Oct 1990		Additional Cost Principles
HHSAR		352.228-7		Dec 1991		Insurance — Liability to Third Persons
HHSAR		352.232-9		Apr 1984		Withholding of Contract Payments
HHSAR		352.233-70		Apr 1984		Litigation and Claims
HHSAR		352.242-71		Apr 1984		Final Decisions on Audit Findings
HHSAR		352.270-5		Apr 1984		Key Personnel
HHSAR		352.270-6		Jul 1991		Publications and Publicity
HHSAR		352.270-7		Jan 2001		Paperwork Reduction Act

I.2. AUTHORIZED SUBSTITUTIONS OF CLAUSES

ARTICLE I.1. of this SECTION is hereby modified as follows:

FAR Clauses 52.219-9, Small Business Subcontracting Plan (September 2006), and 52.219-16, Liquidated Damages—Subcontracting Plan (January 1999) are deleted in their entirety.

FAR Clause 52.232-20, Limitation of Cost, is deleted in its entirety and FAR Clause 52.232-22, Limitation of Funds (APRIL 1984) is substituted therefore. [Note: When this contract is fully funded, FAR Clause 52.232-22, Limitation of Funds will no longer apply and FAR Clause 52.232-20, Limitation of Cost will become applicable.]

I.3. ADDITIONAL CONTRACT CLAUSES

This contract incorporates the following clauses by reference, with the same force and effect, as if they were given in full text. Upon request, the contracting officer will make their full text available.

52.215-17 Waiver of Facilities Capital Cost of Money (October 1997)

52.243-2, Changes—Cost Reimbursement (August 1987)

I.4 Additional Contract Clauses of SECTION I – Added in full text

52.222-39 Notification of Employee Rights Concerning Payment of Union Dues or Fees (Dec 2004)

(a) Definition. As used in this clause—

“United States” means the 50 States, the District of Columbia, Puerto Rico, the Northern Mariana Islands, American Samoa, Guam, the U.S. Virgin Islands, and Wake Island.

(b) Except as provided in paragraph (e) of this clause, during the term of this contract, the Contractor shall post a notice, in the form of a poster, informing employees of their rights concerning union membership and payment of union dues and fees, in conspicuous places in and about all its plants and offices, including all places where notices to employees are customarily posted. The notice shall include the following information (except that the information pertaining to National Labor Relations Board shall not be included

Contract No. HHSO100200700031C		Page 24 of 29

in notices posted in the plants or offices of carriers subject to the Railway Labor Act, as amended (45 U.S.C. 151-188)).

Notice to Employees

Under Federal law, employees cannot be required to join a union or maintain membership in a union in order to retain their jobs. Under certain conditions, the law permits a union and an employer to enter into a union-security agreement requiring employees to pay uniform periodic dues and initiation fees. However, employees who are not union members can object to the use of their payments for certain purposes and can only be required to pay their share of union costs relating to collective bargaining, contract administration, and grievance adjustment.

If you do not want to pay that portion of dues or fees used to support activities not related to collective bargaining, contract administration, or grievance adjustment, you are entitled to an appropriate reduction in your payment. If you believe that you have been required to pay dues or fees used in part to support activities not related to collective bargaining, contract administration, or grievance adjustment, you may be entitled to a refund and to an appropriate reduction in future payments.

For further information concerning your rights, you may wish to contact the National Labor Relations Board (NLRB) either at one of its Regional offices or at the following address or toll free number:

National Labor Relations Board
Division of Information
1099 14th Street, N.W.
Washington, DC 20570
1-866-667-6572
1-866-316-6572 (TTY)
To locate the nearest NLRB office, see NLRB’s website at http://www.nlrb.gov.

(c) The Contractor shall comply with all provisions of Executive Order 13201 of February 17, 2001, and related implementing regulations at 29 CFR Part 470, and orders of the Secretary of Labor.

(d) In the event that the Contractor does not comply with any of the requirements set forth in paragraphs (b), (c), or (g), the Secretary may direct that this contract be cancelled, terminated, or suspended in whole or in part, and declare the Contractor ineligible for further Government contracts in accordance with procedures at 29 CFR Part 470, Subpart B—Compliance Evaluations, Complaint Investigations and Enforcement Procedures. Such other sanctions or remedies may be imposed as are provided by 29 CFR Part 470, which implements Executive Order 13201, or as are otherwise provided by law.

(e) The requirement to post the employee notice in paragraph (b) does not apply to—

(1) Contractors and subcontractors that employ fewer than 15 persons;

(2) Contractor establishments or construction work sites where no union has been formally recognized by the Contractor or certified as the exclusive bargaining representative of the Contractor’s employees;

(3) Contractor establishments or construction work sites located in a jurisdiction named in the definition of the United States in which the law of that jurisdiction forbids enforcement of union-security agreements;

(4) Contractor facilities where upon the written request of the Contractor, the Department of Labor Deputy Assistant Secretary for Labor-Management Programs has waived the posting requirements with respect to any of the Contractor’s facilities if the Deputy Assistant Secretary finds that the Contractor has demonstrated that—

(i) The facility is in all respects separate and distinct from activities of the Contractor related to the performance of a contract; and

(ii) Such a waiver will not interfere with or impede the effectuation of the Executive order; or

(5) Work outside the United States that does not involve the recruitment or employment of workers within the United States.

(f) The Department of Labor publishes the official employee notice in two variations; one for contractors covered by the Railway Labor Act and a second for all other contractors. The Contractor shall—

(1) Obtain the required employee notice poster from the Division of Interpretations and Standards, Office of Labor-Management Standards, U.S. Department of Labor, 200 Constitution Avenue, NW, Room N-5605, Washington, DC 20210, or from any field office of the Department’s Office of Labor-Management Standards or Office of Federal Contract Compliance Programs;

Contract No. HHSO100200700031C		Page 25 of 29

(2) Download a copy of the poster from the Office of Labor-Management Standards website at http://www.olms.dol.gov; or

(3) Reproduce and use exact duplicate copies of the Department of Labor’s official poster.

(g) The Contractor shall include the substance of this clause in every subcontract or purchase order that exceeds the simplified acquisition threshold, entered into in connection with this contract, unless exempted by the Department of Labor Deputy Assistant Secretary for Labor-Management Programs on account of special circumstances in the national interest under authority of 29 CFR 470.3(c). For indefinite quantity subcontracts, the Contractor shall include the substance of this clause if the value of orders in any calendar year of the subcontract is expected to exceed the simplified acquisition threshold. Pursuant to 29 CFR Part 470, Subpart B—Compliance Evaluations, Complaint Investigations and Enforcement Procedures, the Secretary of Labor may direct the Contractor to take such action in the enforcement of these regulations, including the imposition of sanctions for noncompliance with respect to any such subcontract or purchase order. If the Contractor becomes involved in litigation with a subcontractor or vendor, or is threatened with such involvement, as a result of such direction, the Contractor may request the United States, through the Secretary of Labor, to enter into such litigation to protect the interests of the United States.

52.227-14, Rights in Data Alternate II (June 1987)

     (g)(2) Notwithstanding paragraph (g)(1) of this clause, the contract may identify and specify the delivery of limited rights data, or the Contracting Officer may require by written request the delivery of limited rights data that has been withheld or would otherwise be withholdable. If delivery of such data is so required, the Contractor may affix the following “Limited Rights Notice” to the data and the Government will thereafter treat the data, subject to the provisions of paragraphs (e) and (f) of this clause, in accordance with such Notice:

Limited Rights Notice (June 1987)

(a)

These data are submitted with limited rights under Government Contract No. HHSO10020070031C and subcontracts. These data may be reproduced and used by the Government with the express limitation that they will not, without written permission of the Contractor, be used for purposes of manufacture nor disclosed outside the Government; except that the Government may disclose these data outside the Government for the following purposes, if any; provided that the Government makes such disclosure subject to prohibition against further use and disclosure:

(i) Use (except for manufacture) by support service contractors.

(b)

This Notice shall be marked on any reproduction of these data, in whole or in part.

(End of Clause)

I. 5. Department of Health and Human Services Acquisition Regulations (HHSAR)

(48 CFR Chapter 3) Clauses: Full text of these clauses can be found at
http://www.dhhs.gov/oamp/dap/hhsar.html/

352.223-70, Safety and Health (January 2001)

352.224-70, Confidentiality of Information (April 1984)

352.270-5, Key Personnel (April 1984)

Contract No. HHSO100200700031C		Page 26 of 29

352.270-8, Protection of Human Subjects (January 2001)

Note: The Office for Human Research Protections (OHRP), Office of the Secretary (OS), Department of Health and Human Services (DHHS) is the office responsible for oversight of the Protection of Human Subjects and should replace Office for Protection from Research Risks (OPRR), National Institutes of Health (NIH) wherever it appears in this clause.

352.270-9, Care of Live Vertebrate Animals (January 2001)

Contract No. HHSO100200700031C		Page 27 of 29

PART III — LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS

SECTION J — LIST OF ATTACHMENTS

Invoice/Financing Request Instructions (1 page)

Report of Government owned Contractor held property (1 page)

Contractor defined milestones (December 20, 2006, 3 pages)

Contract No. HHSO100200700031C		Page 28 of 29

SECTION K – REPRSENTATIONS AND CERTIFICATIONS

The following documents are incorporated by reference in this contract:

Annual Representations and Certifications completed and located at the Online Representations and Certifications Application (ORCA) website. [This includes the changes if any identified in paragraph (b) of the FAR provision 52.204-8, Annual Representations and Certifications, contained in the contractor’s proposal.]

Contract No. HHSO100200700031C		Page 29 of 29